Company / Operating Income
NovaBay Pharmaceuticals, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$5.8M
FY2024
5-year range
-$14.4M / -$4.1M
FY2020-FY2024
Trend
-42.3%
vs FY2023
Sector context
#57 of 202
Health Care
What the data says
At -$6M, NovaBay Pharmaceuticals, Inc.'s operating income ranks #57 of 202 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$21M in FY2015 to -$4M in FY2023.
Based on SEC 10-K filings.
-$6M in FY2024.
Improved from -$14M to -$6M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#57 of 202 in Health CareTop 28% of 202This company -$5.8M Sector average $86.7M
▼
-106.7% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 42.3% year-over-year.
- Ranks #57 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
- Lowest operating income in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$5.8M | -42.3% |
| FY2023 | -$4.1M | +71.5% |
| FY2022 | -$14.4M | -62.7% |
| FY2021 | -$8.9M | -37.9% |
| FY2020 | -$6.4M | +31.6% |
| FY2019 | -$9.4M | -19.4% |
| FY2018 | -$7.9M | -7.7% |
| FY2017 | -$7.3M | +33.4% |
| FY2016 | -$11.0M | +48.0% |
| FY2015 | -$21.1M | -25.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026